中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 147-150

The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease

DOI: 10.12449/JCH240124

  • Center of Liver Diseases，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

National Natural Science Foundation of China (82170591)

More Information
  • Corresponding author: WANG Qi， wangqidl04@ccmu.edu.cn （ORCID： 0000-0002-0269-1568）
  • Received Date: 2023-04-17
  • Accepted Date: 2023-06-19
  • Published Date: 2024-01-23
    Abstract
  • Nonalcoholic fatty liver disease （NAFLD） has gradually become the main reason affecting human liver health， and many factors are involved in the development and progression of NAFLD. Mitochondria， as the “energy factory” of cells， plays an important role in maintaining normal physiological functions. Studies have shown that hepatic mitochondrial dysfunction promotes the development and progression of NAFLD. This article briefly introduces the latest research advances in the basic characteristics and physiological function of liver mitochondria and reviews new research findings in the association of mitochondrial dysfunction with obesity， simple fatty liver disease， and nonalcoholic steatohepatitis， in order to provide new ideas for the research on targeted mitochondrial therapy for NAFLD.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    TARGHER G, COREY KE, BYRNE CD, et al. The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 9): 599- 612. DOI: 10.1038/s41575-021-00448-y.
    [2]
    PAFILI K, RODEN M. Nonalcoholic fatty liver disease(NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
    [3]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [4]
    NOUREDDIN M, SANYAL AJ. Pathogenesis of NASH: The impact of multiple pathways[J]. Curr Hepatol Rep, 2018, 17( 4): 350- 360. DOI: 10.1007/s11901-018-0425-7.
    [5]
    MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155( 3): 629- 647. DOI: 10.1053/j.gastro.2018.06.083.
    [6]
    CIAULA AD, PASSARELLA S, SHANMUGAM H, et al. Nonalcoholic fatty liver disease(NAFLD). Mitochondria as players and targets of therapies?[J]. Int J Mol Sci, 2021, 22( 10): 5375. DOI: 10.3390/ijms22105375.
    [7]
    XIAO WC, AN W. Role of mitochondrial injury in the development and progression of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 7): 1515- 1521. DOI: 10.3969/j.issn.1001-5256.2021.07.005.

    肖卫纯, 安威. 线粒体损伤在非酒精性脂肪性肝病发生发展中的作用[J]. 临床肝胆病杂志, 2021, 37( 7): 1515- 1521. DOI: 10.3969/j.issn.1001-5256.2021.07.005.
    [8]
    TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375( 6586): 1254- 1261. DOI: 10.1126/science.abf0529.
    [9]
    NI HM, WILLIAMS JA, DING WX. Mitochondrial dynamics and mitochondrial quality control[J]. Redox Biol, 2015, 4: 6- 13. DOI: 10.1016/j.redox.2014.11.006.
    [10]
    YOULE RJ, van DER BLIEK AM. Mitochondrial fission, fusion, and stress[J]. Science, 2012, 337( 6098): 1062- 1065. DOI: 10.1126/science.1219855.
    [11]
    CHOWANADISAI W, BAUERLY KA, TCHAPARIAN E, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression[J]. J Biol Chem, 2010, 285( 1): 142- 152. DOI: 10.1074/jbc.M109.030130.
    [12]
    KOLIAKI C, RODEN M. Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus[J]. Annu Rev Nutr, 2016, 36: 337- 367. DOI: 10.1146/annurev-nutr-071715-050656.
    [13]
    XIAN HX, LIOU YC. Functions of outer mitochondrial membrane proteins: Mediating the crosstalk between mitochondrial dynamics and mitophagy[J]. Cell Death Differ, 2021, 28( 3): 827- 842. DOI: 10.1038/s41418-020-00657-z.
    [14]
    KOLIAKI C, SZENDROEDI J, KAUL K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis[J]. Cell Metab, 2015, 21( 5): 739- 746. DOI: 10.1016/j.cmet.2015.04.004.
    [15]
    POUSSIN C, IBBERSON M, HALL D, et al. Oxidative phosphorylation flexibility in the liver of mice resistant to high-fat diet-induced hepatic steatosis[J]. Diabetes, 2011, 60( 9): 2216- 2224. DOI: 10.2337/db11-0338.
    [16]
    PETERSEN KF, BEFROY DE, DUFOUR S, et al. Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by(13)C magnetic resonance spectroscopy[J]. Cell Metab, 2016, 24( 1): 167- 171. DOI: 10.1016/j.cmet.2016.06.005.
    [17]
    SUNNY NE, PARKS EJ, BROWNING JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease[J]. Cell Metab, 2011, 14( 6): 804- 810. DOI: 10.1016/j.cmet.2011.11.004.
    [18]
    PEDERSEN JS, RYGG MO, CHRØIS K, et al. Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration[J]. Nat Commun, 2022, 13( 1): 2931. DOI: 10.1038/s41467-022-30629-5.
    [19]
    SATAPATI S, KUCEJOVA B, DUARTE JAG, et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver[J]. J Clin Invest, 2016, 126( 4): 1605. DOI: 10.1172/JCI86695.
    [20]
    SHAMI GJ, CHENG D, VERHAEGH P, et al. Three-dimensional ultrastructure of giant mitochondria in human non-alcoholic fatty liver disease[J]. Sci Rep, 2021, 11( 1): 3319. DOI: 10.1038/s41598-021-82884-z.
    [21]
    XU ZX, LUO SZ, XU MY. Mechanism of mitochondrial dysfunction in the development of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36( 10): 2353- 2355. DOI: 10.3969/j.issn.1001-5256.2020.10.042.

    徐梓馨, 罗声政, 徐铭益. 线粒体功能异常在非酒精性脂肪性肝病发生中的机制[J]. 临床肝胆病杂志, 2020, 36( 10): 2353- 2355. DOI: 10.3969/j.issn.1001-5256.2020.10.042.
    [22]
    LI YF, XU JY, LU YT, et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing[J]. Cell Metab, 2021, 33( 10): 2004- 2020. DOI: 10.1016/j.cmet.2021.09.008.
    [23]
    CHAVIN KD, YANG S, LIN HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion[J]. J Biol Chem, 1999, 274( 9): 5692- 5700. DOI: 10.1074/jbc.274.9.5692.
    [24]
    CORTEZ-PINTO H, CHATHAM J, CHACKO VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study[J]. JAMA, 1999, 282( 17): 1659- 1664. DOI: 10.1001/jama.282.17.1659.
    [25]
    MORRIS EM, RECTOR RS, THYFAULT JP, et al. Mitochondria and redox signaling in steatohepatitis[J]. Antioxid Redox Signal, 2011, 15( 2): 485- 504. DOI: 10.1089/ars.2010.3795.
    [26]
    BEGRICHE K, IGOUDJIL A, PESSAYRE D, et al. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it[J]. Mitochondrion, 2006, 6( 1): 1- 28. DOI: 10.1016/j.mito.2005.10.004.
    [27]
    XU JS, CHEN SY, WANG W, et al. Hepatic CDP-diacylglycerol synthase 2 deficiency causes mitochondrial dysfunction and promotes rapid progression of NASH and fibrosis[J]. Sci Bull, 2022, 67( 3): 299- 314. DOI: 10.1016/j.scib.2021.10.014.
    [28]
    MIYAO M, KAWAI C, KOTANI H, et al. Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis[J]. Hepatol Res, 2022, 52( 12): 1020- 1033. DOI: 10.1111/hepr.13832.
    [29]
    MONTEIRO JP, OLIVEIRA PJ, JURADO AS. Mitochondrial membrane lipid remodeling in pathophysiology: A new target for diet and therapeutic interventions[J]. Prog Lipid Res, 2013, 52( 4): 513- 528. DOI: 10.1016/j.plipres.2013.06.002.
    [30]
    MAGKOS F, SU X, BRADLEY D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects[J]. Gastroenterology, 2012, 142( 7): 1444- 1446. DOI: 10.1053/j.gastro.2012.03.003.
    [31]
    APOSTOLOPOULOU M, GORDILLO R, KOLIAKI C, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis[J]. Diabetes Care, 2018, 41( 6): 1235- 1243. DOI: 10.2337/dc17-1318.
    [32]
    OOI GJ, MEIKLE PJ, HUYNH K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 75( 3): 524- 535. DOI: 10.1016/j.jhep.2021.04.013.
    [33]
    GAO RX, LI Y, XU ZM, et al. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 78( 6): 1800- 1815. DOI: 10.1097/HEP.0000000000000279.
    [34]
    LI Y, XIU WJ, XU JW, et al. Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling[J]. JCI Insight, 2022, 7( 23): e162402. DOI: 10.1172/jci.insight.162402.
    [35]
    HE YH, ZHU MX, LIU YY, et al. Research progress of Curcumin and Resveratrol in the treatment of non-alcoholic fatty liver disease[J]. Chin Med Herald, 2023, 20( 1): 57- 60. DOI: 10.20047/j.issn1673-7210.2023.01.12.

    贺玉慧, 朱铭星, 刘跃洋, 等. 姜黄素与白藜芦醇治疗非酒精性脂肪性肝病的机制研究进展[J]. 中国医药导报, 2023, 20( 1): 57- 60. DOI: 10.20047/j.issn1673-7210.2023.01.12.
    [36]
    GEORGIEV A, GRANATA C, RODEN M. The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans[J]. Am J Physiol Cell Physiol, 2022, 322( 6): C1248- C1259. DOI: 10.1152/ajpcell.00035.2022.
    [37]
    GRANATA C, JAMNICK NA, BISHOP DJ. Training-induced changes in mitochondrial content and respiratory function in human skeletal muscle[J]. Sports Med, 2018, 48( 8): 1809- 1828. DOI: 10.1007/s40279-018-0936-y.
    [38]
    THIETART S, RAUTOU PE. Extracellular vesicles as biomarkers in liver diseases: A clinician’s point of view[J]. J Hepatol, 2020, 73( 6): 1507- 1525. DOI: 10.1016/j.jhep.2020.07.014.
    [39]
    AMIR DACHE Z AL, OTANDAULT A, TANOS R, et al. Blood contains circulating cell-free respiratory competent mitochondria[J]. FASEB J, 2020, 34( 3): 3616- 3630. DOI: 10.1096/fj.201901917RR.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (241) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return